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Abstract
Background: We evaluated predictors and outcomes of Mycobacterium tuberculosis bacteremia among participants
undergoing baseline mycobacterial blood culture in the ACTG A5221 STRIDE study, a randomized clinical trial
comparing earlier with later ART among HIV-infected patients suspected of having tuberculosis with CD4-positive
T-lymphocyte counts (CD4 counts) <250 cells/mm
3. We conducted a secondary analysis comparing participants
with respect to presence or absence of M. tuberculosis bacteremia.
Methods: Participants with a baseline mycobacterial blood culture were compared with respect to the presence or
absence of M. tuberculosis bacteremia. Baseline predictors of M. tuberculosis bacteremia were identified and
participant outcomes were compared by mycobacteremia status.
Results: Of 90 participants with baseline mycobacterial blood cultures, 29 (32.2%) were female, the median (IQR)
age was 37 (31–45) years, CD4 count was 81 (33–131) cells/mm
3, HIV-1 RNA level was 5.39 (4.96–5.83) log10 copies/
mL, and 18 (20.0%) had blood cultures positive for M. tuberculosis. In multivariable analysis, lower CD4 count
(OR 0.85 per 10-cell increase, p= 0.012), hemoglobin ≤8.5 g/dL (OR 5.8, p = 0.049), and confirmed tuberculosis
(OR 17.4, p =0.001) were associated with M. tuberculosis bacteremia. There were no significant differences in survival
and AIDS-free survival, occurrence of tuberculosis immune reconstitution inflammatory syndrome (IRIS), or treatment
interruption or discontinuation by M. tuberculosis bacteremia status. IRIS did not differ significantly between groups
despite trends toward more virologic suppression and greater CD4 count increases at week 48 in the bacteremic
group.
Conclusions: Among HIV-infected tuberculosis suspects, lower CD4 count, hemoglobin ≤8.5 g/dL, and the
presence of microbiologically confirmed pulmonary tuberculosis were associated with increased adjusted odds
of mycobacteremia. No evidence of an association between M. tuberculosis bacteremia and the increased risk of
IRIS was detected.
Trial registration: ClinicalTrials.gov: NCT00108862.
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Disseminated tuberculosis is strictly defined as isolation
of Mycobacterium tuberculosis from blood or bone mar-
row, liver biopsy, or from specimens from ≥2 noncontig-
uous organs [1]. Disseminated tuberculosis is associated
with compromised cell-mediated immunity and the
bacteremic form is rapidly fatal in a large proportion of
HIV-infected patients [2]. Early recognition and treat-
ment are likely to be important in improving patient
outcomes. Although research has identified a number of
clinical and laboratory features that may assist with rec-
ognition of patients with bacteremic disseminated tuber-
culosis [2,3], non-specific clinical findings and lack of
typical features of pulmonary tuberculosis complicate
diagnosis. Randomized trials have confirmed that early
initiation of antiretroviral therapy (ART) is associated
with improved outcomes for HIV and tuberculosis co-
infected patients [4-7]. However, these studies have
focused primarily on pulmonary tuberculosis, leaving
unanswered questions about the timing and impact of
ART in patients with confirmed disseminated tubercu-
losis. Research suggests that patients with disseminated
and extra-pulmonary forms of tuberculosis may represent
a special group that may experience worse outcomes, in-
cluding greater risk for the tuberculosis immune recon-
stitution inflammatory syndrome (IRIS) [8,9].
In order to strengthen data on clinical predictors of
M. tuberculosis bacteremia and to assess the effect of
M. tuberculosis bacteremia on ART treatment outcomes
and toxicities, we conducted a planned analysis of patients
enrolled in the AIDS Clinical Trials Group (ACTG) A5221
strategy study of early versus later initiation of antiretro-
viral therapy for HIV-infected persons treated for tubercu-
losis with CD4< 250 cells/mm
3 (STRIDE), who received a
mycobacterial blood culture as part of their baseline evalu-
ation. Participants with and without bacteremic dissemi-
nated tuberculosis were compared.
Methods
ACTG A5221 STRIDE study
A5221 was an open-label, randomized study comparing
earlier ART (within 2 weeks after initiation of treatment
for tuberculosis) with later ART (between 8 and 12 weeks
after initiation of treatment for tuberculosis) in HIV-1 in-
fected patients with CD4-positive T-lymphocyte counts
(CD4 counts) <250 cells/mm
3 and suspected tuberculosis.
The primary endpoint was the proportion of patients who
survived without a new (previously undiagnosed) acquired
immunodeficiency syndrome (AIDS)-defining illness at
48 weeks. Mycobacterial blood cultures were not required
by the protocol. However, all tuberculosis diagnostic infor-
mation was required to be recorded by the study sites.
Mycobacterial blood cultures were not standardized across
sites, but were collected at the discretion of the study team
prior to the administration of tuberculosis treatment
and antiretroviral therapy, and were processed in la-
boratories adhering to Good Clinical Laboratory Prac-
tice standards. Confirmed tuberculosis was defined as
detection of acid-fast bacilli in sputum smear or lymph
node specimen, or a positive culture for Mycobacterium
tuberculosis from sputum, lymph node, or another sterile
site. Probable tuberculosis required clinician’s assessment
that signs and symptoms warranted empiric tuberculosis
treatment. Detailed methods and results of the study
are published elsewhere [7,10] and available at www.
clinicaltrials.gov identifier NCT00108862. The quality of
the data was assured by adherence to Good Clinical Prac-
tice and Good Clinical Laboratory Practice standards.
Mycobacteremia sub-study
Of 806 eligible participants from 26 sites enrolled in
A5221, 90 (11.2%) participants from 5 (19.2%) sites had
baseline mycobacterial blood cultures and were included
in this analysis.
Statistical analysis
Exact logistic regression models were used to investigate
baseline predictors of M. tuberculosis bacteremia. Covari-
ates with p≤0.10 from an exact conditional score test in
univariable models were examined together in a multivari-
able model using the stepwise selection method. Estimated
proportions of participants who survived with or without a
new AIDS event at 48 weeks and failure-time plots were
calculated with the use of the Kaplan–Meier method. Fail-
ure was defined at the first qualifying event. Failure times
were determined as the differences between randomization
and failure dates or, if censored, last clinical visit dates.
An asymptotic normal two-sample test was employed to
evaluate the difference in failure proportions. Fisher’s
exact and exact Wilcoxon tests were used to assess
between-group differences. Based on the sample sizes and
numbers of primary endpoint, there was 12% power to de-
tect a difference using a two-sided 0.05-level binomial test.
Participant characteristics at baseline, including sex; en-
rollment at an African site; age; CD4 count; HIV-1 RNA
level; presence of an AIDS-defining illness; body mass
index (BMI); hemoglobin; self-reported cough, weight loss,
and fever; and confirmed tuberculosis, were evaluated as
potential predictors of M. tuberculosis bacteremia in a uni-
variable exact logistic regression model.
Research ethics
The protocol was approved by the following institutional
review boards or ethics committees: New York University
School of Medicine, NY, USA; Los Angeles Biomedical Re-
search Institute, CA, USA; University of California San
Diego, CA, USA; University of California San Francisco,
CA, USA: University of Southern California, CA, USA;
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Witwatersrand, Johannesburg, South Africa; University of
KwaZulu Natal, Durban, South Africa; Asociacion Civil
Impacta Salud y Educacion, Lima, Peru; Chiang Mai Uni-
versity Research Institute for Health Sciences and Faculty
of Medicine Chiang Mai University, Chiang Mai, Thailand;
National AIDS Research Institute, Pune, India; YRG Care
Medical Centre, Chennai, India; National Health Science
Research Committee, Lilongwe, Malawi, and University of
North Carolina, NC, USA; Instituto de Pequisa Clinica
Evandro Chagas, Rio de Janeiro, Brazil; Grupo Hospitalar
Conceicao, Porto Alegre, Brazil; Joint Clinical Research
Centre and Uganda National Council for Science and
Technology, Kampala, Uganda; Kenya Medical Research
Institute, Nairobi, Kenya; Moi University College of Health
Sciences, Eldoret, Kenya; Health Research and Knowledge
Management, Gaborone, Botswana, and Harvard School
of Public Health, MA, USA; University of Zambia, Lusaka,
Zambia, and University of Alabama at Birmingham, AL,
USA; Comite des Droits Humains des Centres GHESKIO,
Port-au-Prince, Haïti; Johns Hopkins University, MD,
USA, and University of Malawi, Blantyre, Malawi; Medical
Research Council of Zimbabwe, Harare, Zimbabwe;
Hospital Universitario Clementino Fraga Filho, Rio de
Janeiro, Brazil; Bronx-Lebanon Hospital Center, NY, USA;
University of Texas Health Science Center at Houston,
TX, USA; and University of Medicine and Dentistry of
New Jersey Newark Campus, NJ, USA. All participants
provided written informed consent.
Results
Participant characteristics
Eighty-eight (97.8%) of 90 participants with baseline myco-
bacterial blood cultures were from sites in Rio de Janeiro,
Brazil; Lilongwe, Malawi; and Johannesburg, South Africa.
Among all participants from these 3 sites, those with myco-
bacterial blood cultures were more often enrolled at a non-
African site (p< 0.001), older (p=0.017), and more likely to
report cough (p=0.022) and weight loss (p<0.001) com-
pared with participants without cultures (Table 1). Of all 90
participants with baseline mycobacterial blood cultures, 29
(32.2%) were female, the median (IQR) age was 37 (31–45)
years, CD4 count was 81 (33–131) cells/mm
3,a n dH I V - 1
RNA level was 5.39 (4.96–5.83) log10 copies/mL. Forty-two
(46.7%) of 90 participants started early ART and 18 (20.0%)
of 90 were blood culture positive for M. tuberculosis.O f
those with mycobacteremia, 10 (55.6%) had positive base-
line sputa for acid-fast bacilli, and 17 (94.4%) met the study
definition of confirmed tuberculosis and 1 (5.6%) met the
definition of probable tuberculosis at week 12.
Baseline predictors of M. tuberculosis bacteremia
The covariates that were significantly (p≤ 0.10) associ-
ated with higher odds of M. tuberculosis bacteremia
were female sex (OR 2.6, 90% CI 0.93, 7.2; p =0.092),
younger age (OR 0.94, 90% CI 0.89, 0.99; p =0.058),
lower CD4 count (OR 1.2 per 10-cell decrease, 90%
CI 1.1, 1.4; p =0.003), higher HIV-1 RNA level (OR
2.2, 90% CI 1.1, 4.8; p =0.048), lower BMI (OR 0.82,
90% CI 0.69, 0.96; p =0.053), hemoglobin ≤8.5 g/dL (OR
5.5, 90% CI 1.8, 17.1; p=0.005), and confirmed tubercu-
losis (OR 19.6, 90% CI 3.4, 424.2; p=0.003). In the multi-
variable analysis, lower CD4 count (adjusted OR 1.2 per
10-cell decrease, 90% CI 1.0, 1.4; p=0.012), hemoglobin
≤8.5 g/dL (adjusted OR 5.8, 90% CI 1.2, 34.4; p=0.049),
and confirmed tuberculosis (adjusted OR 17.4, 90% CI 2.6,
410.1; p=0.001) were associated with increased adjusted
odds of M. tuberculosis bacteremia.
Survival and survival without a new AIDS-defining event
at 48 weeks
There were 2 (11.1%) deaths out of 18 participants in
the group with M. tuberculosis bacteremia compared
with 6 (8.3%) deaths out of 72 participants in the non-
bacteremic group. The estimated difference in propor-
tions at week 48 between the two groups was −2.5%
(95% CI −18.5%, 13.4%; p=0.76). There were 4 (22.2%)
events (1 death and 3 new AIDS-defining illnesses
(1 then died) out of 18 participants in the group with
M. tuberculosis bacteremia compared with 11 (15.3%)
events (4 deaths and 7 new AIDS-defining illnesses (2
then died)) out of 72 participants in the group without.
The estimated difference in event proportions at week 48
was −6.6% (95% CI −27.6%, 14.3%; p=0.54). No signifi-
cant differences were observed using Fisher’s exact test in
subgroup analyses (within CD4<50 cells/mm
3 and ≥50
cells/mm
3; early ART and late ART). The Figure 1 shows
time-to-first new AIDS-defining illness or death.
Other participant outcomes by M. tuberculosis bacteremia
status
Table 2 shows participant outcomes by M. tuberculosis
bacteremia status. There were no differences by M. tuber-
culosis bacteremia in the occurrence of IRIS, in interruption
or discontinuation of tuberculosis medications or ART due
to drug toxicity, or in sputum culture conversion from
positive at baseline to negative at week 8. Participants with
M. tuberculosis bacteremia were significantly more likely to
convert their sputum smear from positive at baseline to
negative at week 8 (70% versus 20%; p=0.008). The higher
proportion of participants with sputum conversion in the
M. tuberculosis bacteremia group remained significant
when missing baseline smear results were coded as positive
(p=0.036) or as negative (p=0.007). The difference
remained significant in an analysis adjusting for timing of
ART initiation and CD4 count strata (exact logistic regres-
sion M. tuberculosis bacteremia group conditional score
Crump et al. BMC Infectious Diseases  (2015) 15:12  Page 3 of 7test p=0.02). There were non-significant trends in partici-
pants with M. tuberculosis bacteremia being more likely
to have HIV-1 RNA levels <400 copies/mL at week 48
(p=0.062) and experiencing CD4 count increases ≥100
cells/mm
3 at week 48 (p = 0.059).
Discussion
We demonstrated that lower CD4 count, hemoglo-
bin ≤8.5 g/dL, and the presence of microbiologically
confirmed tuberculosis were associated with increased
adjusted odds of M. tuberculosis bacteremia among
HIV-infected patients suspected to have tuberculosis.
We found no significant differences in survival or AIDS-
free survival, occurrence of IRIS, or treatment interrup-
tion or discontinuation by M. tuberculosis bacteremia
status. Occurrence of IRIS did not significantly differ be-
tween groups [8], despite trends toward more virologic
suppression and greater CD4 count increases at week 48
Figure 1 Time-to-first new AIDS-defining illness or death among participants with and without mycobacteremia, ACTG A5221
STRIDE study.
Table 1 Baseline characteristics by blood culture availability among participants enrolled at the three sites that
collected nearly all the baseline blood cultures, ACTG A5221 STRIDE study
Baseline blood culture available
Total Yes No p-value
a
n/ n (%) n/ n (%) n/ n (%)
Baseline characteristics
Male sex 137/ 226 (60.6) 59/ 88 (67.0) 78/ 138 (56.5) 0.126
Enrollment at an African site 158/ 226 (69.9) 38/ 88 (43.2) 120/ 138 (87.0) <0.001
Age (years)
b 34.0 (29.0, 42.0) 36.5 (30.5, 44.5) 33.0 (28.0, 41.0) 0.017
CD4 count (cells/mm
3)
b 81.5 (37.0, 132.0) 81.5 (31.5, 131.5) 79.5 (41.0, 134.0) 0.820
HIV RNA (log10 copies/mL)
b 5.4 (5.0, 5.8) 5.4 (5.0, 5.8) 5.4 (5.0, 5.8) 0.796
Presence of an AIDS-defining illness 16/ 226 (7.1) 8/ 88 (9.1) 8/ 138 (5.8) 0.427
Body mass index (BMI, kg/m
2)
b 19.2 (17.5, 21.5) 18.9 (17.2, 20.9) 19.3 (17.8, 21.9) 0.236
Hemoglobin ≤8.5 g/dL 43/ 226 (19.0) 17/ 88 (19.3) 26/ 138 (18.8) 1.000
Self-reported cough 4/ 226 (1.8) 4/ 88 (4.5) 0/ 138 (0.0) 0.022
Self-reported weight loss 11/ 226 (4.9) 11/ 88 (12.5) 0/ 138 (0.0) <0.001
Self-reported fever 2/ 226 (0.9) 2/ 88 (2.3) 0/ 138 (0.0) 0.151
Confirmed tuberculosis at entry 111/ 226 (49.1) 48/ 88 (54.5) 63/ 138 (45.7) 0.220
aFisher’s Exact test, except for age, CD4 count, HIV RNA, and BMI which were exact Wilcoxon test.
bMedian (IQR) values are presented for age, CD4 count, HIV RNA, and BMI.
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with patients without M. tuberculosis bacteremia, myco-
bacteremic patients were more likely to convert their
sputum smear from positive at baseline to negative at
week 8.
Lower CD4 count, hemoglobin ≤8.5 g/dL, and the
presence of microbiologically confirmed tuberculosis
may assist clinicians in identifying tuberculosis suspects
with M. tuberculosis bacteremia and we suggest that
these be included in larger studies developing clinical
diagnostic strategies for disseminated tuberculosis. Unlike
studies of disseminated tuberculosis done among febrile
patients, we did not detect an association between
cough, fever, or weight loss and M. tuberculosis bacteremia.
This is probably because A5221 enrolled tuberculosis
suspects who would be expected to have cough, fever,
or weight loss irrespective of the co-occurrence of
M. tuberculosis bacteremia.
The case fatality ratio of patients with M. tuberculosis
bacteremia was much lower in A5221 than in other
studies [2,11], and there were no significant differences
in survival or AIDS-free survival of HIV and tuberculosis
co-infected patients by mycobacteremia status. Possible
explanations for the better outcomes observed in this
study include that A5221 entry criteria would have ex-
cluded the most severely ill patients; initiation of ART
and tuberculosis treatment may have been more timely
in the clinical trial than would be the case under pro-
gram conditions; and that some patients with occult pre-
sentations of disseminated tuberculosis could have been
overlooked through a focus on features of clinical tuber-
culosis. The lack of differences in survival and AIDS-free
survival between the groups may suggest that mycobac-
teremia does not have the prognostic value in the HIV-
infected tuberculosis suspect population that it does in
the febrile illness population [12], or may simply be due
to lack of power to detect a difference.
The higher total body mycobacterial load assumed
to be present in patients with the bacteremic dissemi-
nated form of tuberculosis combined with rapid ART-
Table 2 Participant characteristics and outcomes by M. tuberculosis bacteremia status, ACTG A5221 STRIDE study
M. tuberculosis bacteremia
Total Yes No p-value
a
n/ n (%) n/ n (%) n/ n (%)
Participant characteristics
Male sex 61/ 90 (67.8) 9/ 18 (50.0) 52/ 72 (72.2) 0.092
Enrollment at an African site 38/ 90 (42.2) 9/ 18 (50.0) 29/ 72 (40.3) 0.595
Age (years)
b 37.0 (31.0, 45.0) 33.0 (29.0, 37.0) 38.0 (31.0, 45.4) 0.056
CD4 count (cells/mm
3)
b 81.0 (33.0, 131.0) 35.0 (16.0, 62.0) 91.0 (39.0, 146.5) <0.001
HIV RNA (log10 copies/mL)
b 5.4 (5.0, 5.8) 5.7 (5.4, 5.9) 5.3 (4.8, 5.8) 0.019
Presence of an AIDS-defining illness 8/ 90 (8.9) 2/ 18 (11.1) 6/ 72 (8.3) 0.658
Body mass index (BMI, kg/m
2)
b 18.9 (17.2, 20.9) 17.3 (15.6, 20.6) 19.2 (17.9, 21.1) 0.026
Hemoglobin ≤8.5 g/dL 17/ 90 (18.9) 8/ 18 (44.4) 9/ 72 (12.5) 0.005
Self-reported cough 4/ 90 (4.4) 1/ 18 (5.6) 3/ 72 (4.2) 1.000
Self-reported weight loss 12/ 90 (13.3) 4/ 18 (22.2) 8/ 72 (11.1) 0.248
Self-reported fever 2/ 90 (2.2) 0/ 18 (0.0) 2/ 72 (2.8) 1.000
Confirmed tuberculosis at entry 50/ 90 (55.6) 17/ 18 (94.4) 33/ 72 (45.8) <0.001
Early ART initiation 42/ 90 (46.7) 9/ 18 (50.0) 33/ 72 (45.8) 0.796
Outcome
Immune reconstitution inflammatory syndrome 11/ 90 (12.2) 2/ 18 (11.1) 9/ 72 (12.5) 1.000
HIV-1 RNA level <400 copies/mL at week 48 69/ 82 (84.1) 16/ 16 (100.0) 53/ 66 (80.3) 0.062
CD4 count increase ≥100 cells/mm
3 at week 48 63/ 85 (74.1) 15/ 16 (93.8) 48/ 69 (69.6) 0.059
Interruption or discontinuation of tuberculosis medications 22/ 90 (24.4) 7/ 18 (38.9) 15/ 72 (20.8) 0.131
Interruption or discontinuation of ART
c 7/ 85 (8.2) 3/ 16 (18.8) 4/ 69 (5.8) 0.120
Sputum smear conversion baseline to week 8
d 12/ 35 (34.3) 7/ 10 (70.0) 5/ 25 (20.0) 0.008
Sputum culture conversion baseline to week 8
d 17/ 23 (73.9) 3/ 4 (75.0) 14/ 19 (73.7) 1.000
aFisher’s Exact test, except for age, CD4 count, HIV RNA, BMI, sputum smear and culture conversion which were exact Wilcoxon test.
bMedian (IQR) values are presented for age, CD4 count, HIV RNA, and BMI.
cART: antiretroviral therapy.
dFrom positive to negative.
Crump et al. BMC Infectious Diseases  (2015) 15:12  Page 5 of 7associated immune reconstitution has been suggested
to increase the risk for IRIS [13]. It is reassuring that
M. tuberculosis bacteremia was not associated with in-
creased risk for IRIS in our analysis despite the high pro-
portion achieving virologic suppression and CD4 count
increases ≥100 cells/mm
3 at week 48.
Compared with patients without M. tuberculosis bacteremia,
mycobacteremic patients were more likely to convert their
sputum smear from positive at baseline to negative at
week 8. This could reflect differences in mycobacterial
burden in the respiratory tract of patients with dissemi-
nated tuberculosis compared with those with primarily
pulmonary disease.
This analysis had a number of limitations. A5221 was
not powered to examine the effect of M. tuberculosis
bacteremia on patient outcomes. The use of mycobacter-
ial blood culture during the baseline evaluation of
ACTG protocol A5221 varied considerably by site and
was at the discretion of the site team. This could have
introduced bias. Misclassification may have occurred in
the control group since not all patients without myco-
bacteremia were ultimately confirmed to have tubercu-
losis and a single mycobacterial blood culture is not
100% sensitive for the detection of mycobacteremia.
Conclusions
Among HIV-infected tuberculosis suspects, mycobacter-
emia was associated with lower CD4 count, hemoglobin
≤8.5 g/dL, and the presence of microbiologically con-
firmed tuberculosis. Tuberculosis suspects with myco-
bacteremia were more likely to convert their sputum
smear from positive at baseline to negative at week 8,
but did not otherwise significantly differ by outcome
compared to those without M. tuberculosis bacteremia.
Most notably, M. tuberculosis bacteremia did not appear
to be associated with increased risk for IRIS despite the
high proportion achieving virologic suppression and
CD4 count increases ≥100 cells/mm
3 at week 48. How-
ever, larger studies with standardized and consistent use
of mycobacterial blood culture are needed to confirm
the findings of our analysis.
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